Diferencia entre revisiones de «Template:Epiglottitis Antibiotics»

(Convert to {{AntibioticDose}} for SMW antibiotic-disease linking)
(Add pediatric immunocompetent and immunocompromised dosing)
 
(No se muestra una edición intermedia del mismo usuario)
Línea 2: Línea 2:


====Immunocompetent====
====Immunocompetent====
*{{AntibioticDose|drug=Ceftriaxone|dose=2gm IV once daily|context=Immunocompetent}} (first line) OR
*{{AntibioticDose|disease=Epiglottitis|drug=Ceftriaxone|dose=2gm IV once daily|context=Immunocompetent}} (first line) OR
*{{AntibioticDose|drug=Cefotaxime|dose=2gm (50mg/kg) IV three times daily|context=Immunocompetent}} OR
*{{AntibioticDose|disease=Epiglottitis|drug=Cefotaxime|dose=2gm (50mg/kg) IV three times daily|context=Immunocompetent}} OR
*{{AntibioticDose|drug=Ampicillin/Sulbactam|dose=3g (50mg/kg) IV q 6 hours|context=Immunocompetent}} OR
*{{AntibioticDose|disease=Epiglottitis|drug=Ampicillin/Sulbactam|dose=3g (50mg/kg) IV q 6 hours|context=Immunocompetent}} OR
*{{AntibioticDose|drug=Levofloxacin|dose=750mg IV once daily|context=Immunocompetent}}
*{{AntibioticDose|disease=Epiglottitis|drug=Levofloxacin|dose=750mg IV once daily|context=Immunocompetent}}
*Consider {{AntibioticDose|drug=Vancomycin|dose=15-20mg/kg IV|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>
*Consider {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15-20mg/kg IV|context=Immunocompetent, MRSA risk}} to any of the above if risk of [[MRSA]]<ref>Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.</ref>


====Immunocompromised====
====Immunocompromised====
Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans
*{{AntibioticDose|drug=Cefepime|dose=2g (50/kg) IV q8 hours|context=Immunocompromised}} AND {{AntibioticDose|drug=Vancomycin|dose=15mg/kg IV q6 hours|context=Immunocompromised}}
*{{AntibioticDose|disease=Epiglottitis|drug=Cefepime|dose=2g (50/kg) IV q8 hours|context=Immunocompromised}} AND {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15mg/kg IV q6 hours|context=Immunocompromised}}
 
====Pediatric Immunocompetent====
*{{AntibioticDose|disease=Epiglottitis|drug=Ceftriaxone|dose=50-100mg/kg IV daily (max 2g)|context=Pediatric Immunocompetent|population=Pediatric}} (first line) OR
*{{AntibioticDose|disease=Epiglottitis|drug=Cefotaxime|dose=50mg/kg IV q8hrs (max 2g/dose)|context=Pediatric Immunocompetent|population=Pediatric}} OR
*{{AntibioticDose|disease=Epiglottitis|drug=Ampicillin/Sulbactam|dose=50mg/kg IV q6hrs (max 3g/dose)|context=Pediatric Immunocompetent|population=Pediatric}}
*Consider {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15mg/kg IV q6hrs|context=Pediatric, MRSA risk|population=Pediatric}} if risk of [[MRSA]]
 
====Pediatric Immunocompromised====
*{{AntibioticDose|disease=Epiglottitis|drug=Cefepime|dose=50mg/kg IV q8hrs (max 2g)|context=Pediatric Immunocompromised|population=Pediatric}} AND {{AntibioticDose|disease=Epiglottitis|drug=Vancomycin|dose=15mg/kg IV q6hrs|context=Pediatric Immunocompromised|population=Pediatric}}

Revisión actual - 12:52 20 mar 2026

Coverage targets Streptococcus pneumoniae, Staphylococcus pyogenes, and Haemophilus influenzae, and H. parainfluenzae

Immunocompetent

Immunocompromised

Coverage should extend to all of the typical organisms above as well as Pseudomonas, M. tuberculosis, and C. albicans

Pediatric Immunocompetent

Pediatric Immunocompromised

  1. Young LS, Price CS. Complicated adult epiglottitis due to methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. Nov-Dec 2007;28(6):441-3.